Tag: nasdaq:cwbr

November 6, 2019

8 Anti-aging Stocks in the US

It can be tough to find public anti-aging companies to invest in, but it's certainly possible with a little time...
November 6, 2019

CohBar Completes Phase 1a and Initiates Phase 1b Stage of Clinical Trial of CB4211 Under Development for NASH and Obesity

CohBar announced the completion of the Phase 1a stage of the ongoing Phase 1a/1b study evaluating the safety, tolerability, and...
May 3, 2019

CohBar to Resume its Phase 1a/1b Clinical Trial

CohBar (NASDAQ:CWBR) has announced it will be resuming its Phase 1a/1b clinical trial of CB4211 after concluding conversations with the...
December 2, 2018

5 Top Weekly NASDAQ Biotech Stocks: Arsanis Gains 271 Percent

Arsanis, Tyme Technologies, CohBar, Cocrystal Pharma and Contrafect were last week's top gainers.
July 12, 2018

CohBar Initiates Clinical Study with First-in-human Dosing of CB4211, a Novel Mitochondria Based Therapeutic for the Treatment of NASH

CohBar (NASDAQ:CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics (MBTs) to treat age-related diseases, today announced that it...